Drugs / hIDS Donor
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03041324 | May 2017 → May 2021 | mucopolysaccharidosis type 2 | Sangamo Therapeutics | Terminated | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hIDS Donor | “Single dose of each of the 3 components of SB-913: ZFN1, ZFN2 and hIDS Donor” NCT03041324 ↗ |